TY - JOUR
T1 - Resilience to cognitive impairment in the oldest-old
T2 - Design of the EMIF-AD 90+ study
AU - Legdeur, Nienke
AU - Badissi, Maryam
AU - Carter, Stephen F.
AU - De Crom, Sophie
AU - Van De Kreeke, Aleid
AU - Vreeswijk, Ralph
AU - Trappenburg, Marijke C.
AU - Oudega, Mardien L.
AU - Koek, Huiberdina L.
AU - Van Campen, Jos P.
AU - Keijsers, Carolina J.P.W.
AU - Amadi, Chinenye
AU - Hinz, Rainer
AU - Gordon, Mark F.
AU - Novak, Gerald
AU - Podhorna, Jana
AU - Serné, Erik
AU - Verbraak, Frank
AU - Yaqub, Maqsood
AU - Hillebrand, Arjan
AU - Griffa, Alessandra
AU - Pendleton, Neil
AU - Kramer, Sophia E.
AU - Teunissen, Charlotte E.
AU - Lammertsma, Adriaan
AU - Barkhof, Frederik
AU - Van Berckel, Bart N.M.
AU - Scheltens, Philip
AU - Muller, Majon
AU - Maier, Andrea B.
AU - Herholz, Karl
AU - Visser, Pieter Jelle
PY - 2018/11/26
Y1 - 2018/11/26
N2 - Background: The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study. Methods: The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures. Discussion: The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration. Trial registration: Nederlands Trial Register NTR5867. Registered 20 May 2016.
AB - Background: The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study. Methods: The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures. Discussion: The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration. Trial registration: Nederlands Trial Register NTR5867. Registered 20 May 2016.
KW - Alzheimer's disease
KW - Amnestic mild cognitive impairment
KW - Amyloid
KW - Cognitive impairment
KW - Dementia
KW - Magnetoencephalography (MEG)
KW - Oldest-old
KW - Positron emission tomography
KW - Resilience
UR - http://www.scopus.com/inward/record.url?scp=85057257495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057257495&partnerID=8YFLogxK
U2 - 10.1186/s12877-018-0984-z
DO - 10.1186/s12877-018-0984-z
M3 - Article
C2 - 30477432
AN - SCOPUS:85057257495
SN - 1471-2318
VL - 18
SP - 1
EP - 16
JO - BMC Geriatrics
JF - BMC Geriatrics
M1 - 289
ER -